In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats
References (19)
- et al.
Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes
Eur. J. Pharmacol.
(1995) - et al.
Overview of chemical sampling techniques
J. Neurosci. Methods
(1993) - et al.
Pre- and postsynaptic localization of a metabotropic glutamate receptor, mGluR2, in the rat brain: an immunohistochemical study with a monoclonal antibody
Neurosci. Lett.
(1996) - et al.
The metabotropic glutamate receptors mGluR2, and mGluR3, show unique postsynaptic, presynaptic and glial localizations
Neuroscience
(1996) - et al.
The metabotropic glutamate receptors: Structure and functions
Neuropharmacology
(1995) - et al.
trans-ACPD and L-APB presynaptically inhibit excitatory glutamatergic transmission in the basolateral amygdala (BLA)
Neurosci. Lett.
(1992) - et al.
Metabotropic glutamate receptors in brain function and pathology
Trends Pharmacol. Sci.
(1993) - et al.
Metabotropic glutamate group II receptors are responsible for the depression of synaptic transmission induced by ACPD in the dentate gyrus
Eur. J. Pharmacol.
(1995) - et al.
A metabotropic glutamate receptor agonist DCG-IV suppresses synaptic transmission at mossy fiber pathway of the guinea pig hippocampus
Neurosci. Lett.
(1996)
Cited by (142)
Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice
2021, Neuroscience LettersCitation Excerpt :Excitotoxicity mediated by corticostriatal release of glutamate, made harmful by either excessive release or excessive postsynaptic activation of extrasynaptic NMDA receptors, has also been proposed to be involved in HD pathogenesis [27,28], and may also be among the additional processes that make R6/2 pathogenesis more rapid than seemingly could be achieved by cortical knockout of BDNF expression alone [1,2,6]. Corticostriatal and thalamostriatal terminals are enriched in mGluR2/3, which are negatively coupled to adenylyl cyclase [29] and thereby act as autoreceptors that dampen glutamate release [30-32]. An mGluR2/3 agonist such as LY379268 reduces glutamate release and thereby reduces activation of extrasynaptic NMDA-type glutamate receptors, which are thought to underlie excitotoxic injury to striatal neurons in HD [27,33].
A role for nucleus accumbens glutamate in the expression but not the induction of behavioural sensitization to ethanol
2018, Behavioural Brain ResearchCitation Excerpt :The mGlu2/3 agonist, LY354740 (Tocris Bioscience), was dissolved in saline with dimethylsulfoxide to a 0.01% final concentration and was administered at 10 mg/kg, i.p., at an injection volume of 15 mL/kg, 20 min prior to EtOH administration. This dosing and time regimen has previously been shown to block striatal synaptic glutamate release [57,58]. MK-801(Sigma-Aldrich) was dissolved in physiological saline and administered i.p. at a concentration of 0.25 mg/kg in a volume of 15 mL/kg, 30 min prior to EtOH administration, as has been used previously in ethanol and psychostimulant sensitization studies [20,41,42,45].